tollip Antibody

What is Tollip and what cellular functions does it regulate?

Tollip is an innate immunity signaling adaptor molecule primarily expressed in myeloid cells, initially recognized as an inhibitor for the TLR signaling pathway . Recent studies have expanded our understanding of Tollip's functions, showing it may modulate cellular autophagy and other pathways in monocytes . In neutrophils, Tollip serves as a molecular checkpoint that governs decision-making processes related to the tumor immune environment . The protein is encoded by the TOLLIP gene in humans and may also be known as IL-1RAcPIP and adapter protein . Structurally, the protein is approximately 30.3 kilodaltons in mass, with orthologs found in canine, porcine, monkey, mouse and rat models .

How does Tollip regulate neutrophil function in cancer biology?

Tollip plays a critical role in determining neutrophil phenotype and function within the tumor microenvironment. In neutrophils, Tollip influences the expression of key immunomodulatory molecules, with Tollip-deficient neutrophils exhibiting elevated levels of costimulatory molecule CD80 and reduced levels of coinhibitory PD-L1 . This altered expression profile appears to be mediated through changes in STAT signaling, specifically the induction of STAT5 and reduction of STAT1 . Functionally, these changes reduce the immunosuppressive effects of neutrophils on T cell proliferation, as demonstrated in coculture experiments where Tollip-deficient neutrophils showed less suppression of both CD4+ and CD8+ T cell proliferation compared to wild-type neutrophils . These findings suggest that Tollip acts as a regulatory switch determining whether neutrophils will suppress or promote T cell responses in tumor environments.

What evidence supports Tollip's role in colorectal cancer development?

Studies using the azoxymethane–dextran sulfate sodium salt (AOM-DSS) colorectal cancer model have demonstrated that Tollip-deficient mice exhibit approximately 50% reduction in both microscopic and macroscopic polyps compared to wild-type counterparts . Histological assessments reveal less severe inflammation and altered epithelial structure in Tollip-deficient mice, with significantly reduced expression of tumor markers including Ki67 and β-catenin . Additionally, Tollip deficiency enhances antitumor immune responses by increasing CD4+ and CD8+ T cell populations in the lamina propria and elevating levels of IFN-γ and IL-12 within colon tissues . Circulating inflammatory cytokine IL-1β was reduced in Tollip-deficient mice, while TGF-β levels were significantly higher compared to wild-type mice after AOM-DSS challenge . These findings collectively indicate that Tollip plays a crucial role in colorectal tumorigenesis, likely by modulating the immune environment.

What applications are Tollip antibodies commonly used for in research?

Tollip antibodies are essential tools in immunological and cancer research, with applications spanning multiple techniques. Based on available commercial antibodies, common applications include:

• Western Blot (WB): For detection and quantification of Tollip protein expression levels in cell or tissue lysates

• Immunohistochemistry (IHC-p): For localization of Tollip in paraffin-embedded tissue sections

• Immunocytochemistry (ICC): For cellular localization studies

• Immunofluorescence (IF): For high-resolution imaging of Tollip distribution

• Flow Cytometry (FCM): For quantitative analysis of Tollip expression in specific cell populations

These applications allow researchers to investigate Tollip's role in various biological processes, particularly in immune regulation and cancer development. Most commercially available antibodies are reactive with human Tollip, though some cross-react with mouse and other species models .

How can researchers design experiments to investigate Tollip's role in neutrophil-mediated T cell activation?

Understanding Tollip's impact on neutrophil-T cell interactions requires carefully designed experiments that account for the complex interplay between these cell types. Based on published research, an effective experimental approach should include:

• Cell Preparation Protocol:

  • Neutrophil isolation: Use density gradient separation with Ficoll-Hypaque followed by dextran sedimentation

  • T cell preparation: Isolate from splenocytes using negative selection and label with CFSE for proliferation tracking

  • Neutrophil conditioning: Prime with GM-CSF (100 ng/ml) overnight to mimic the tumor environment, as this has been shown to induce the immunosuppressive phenotype

• Coculture System Setup:

  • Plate neutrophils (WT and Tollip-deficient) with CFSE-labeled T cells at multiple ratios (1:1, 1:2, 1:5)

  • Activate T cells using anti-CD3 antibody coating (1-5 μg/ml) with soluble anti-CD28 (1 μg/ml)

  • Include appropriate controls: T cells alone, unstimulated T cells, and isotype controls

• Mechanistic Investigation:

  • Include blocking antibodies for PD-L1 and CD80 to directly test their roles in the observed effects

  • Analyze phosphorylation status of STAT1 and STAT5 in neutrophils to connect Tollip to downstream signaling

  • Measure multiple T cell activation parameters: proliferation (CFSE dilution), activation markers (CD69, CD25), and functional outputs (IFN-γ production, cytotoxicity markers)

This experimental design allows researchers to directly assess how Tollip expression in neutrophils influences their capacity to regulate T cell activation, providing mechanistic insights into Tollip's role in tumor immunology.

What considerations are important when analyzing contradictory data regarding Tollip expression in different experimental models?

Researchers often encounter seemingly contradictory results when studying Tollip across different experimental models. To effectively address these discrepancies:

• Context-Dependent Function Analysis:

  • Consider inflammatory status: Tollip may have different functions in acute versus chronic inflammation

  • Disease stage differentiation: Analyze whether Tollip expression and function vary between early and advanced disease states

  • Microenvironmental factors: Document cytokine milieu and cellular composition of the tissue environment

• Technical Validation Strategy:

  • Employ multiple antibody clones targeting different Tollip epitopes to confirm expression patterns

  • Include genetic controls (Tollip-knockout tissues/cells) to validate antibody specificity

  • Use complementary techniques (WB, IHC, flow cytometry) to cross-validate findings

• Cell Type-Specific Analysis:

  • Isolate specific cell populations before analysis to avoid averaging effects across heterogeneous samples

  • Perform single-cell analyses to identify potential cellular subsets with distinct Tollip expression patterns

  • Compare results between neutrophils and monocytes, as Tollip may have cell type-specific functions

• Data Integration Framework:

  • Develop models that accommodate conditional or context-dependent functions

  • Use computational approaches to integrate data across experimental systems

  • Design direct comparison experiments that test specific hypotheses about context-dependent functions

By systematically addressing these variables, researchers can develop more nuanced models of Tollip biology that account for its potentially diverse roles across different biological contexts.

How should researchers evaluate the relationship between Tollip expression and immune checkpoint molecules like PD-L1 and CD80?

Given Tollip's newly discovered role in regulating immune checkpoint molecules, researchers should implement comprehensive analytical approaches:

• Multiplex Expression Analysis:

  • Flow cytometry: Design panels that simultaneously measure Tollip, PD-L1, and CD80 expression in neutrophils

  • Multiplex immunofluorescence: Visualize spatial relationships between Tollip and checkpoint molecules in tissue sections

  • Western blot: Perform correlation analysis between Tollip expression levels and checkpoint molecules across multiple samples

• Dynamic Regulation Studies:

  • Time-course experiments: Monitor changes in Tollip, PD-L1, and CD80 expression following stimulation

  • Signaling pathway analysis: Investigate how Tollip influences STAT1/STAT5 pathways that regulate PD-L1 and CD80

  • Genetic manipulation: Use siRNA or CRISPR approaches to modulate Tollip levels and observe effects on checkpoint molecules

• Functional Validation:

  • T cell suppression assays: Directly test how modulating Tollip affects neutrophil-mediated T cell regulation

  • Blocking antibody experiments: Use anti-PD-L1 or anti-CD80 antibodies to confirm their roles in Tollip-mediated effects

  • In vivo models: Evaluate tumor growth and immune infiltration in models with Tollip manipulation

This integrated approach allows researchers to establish not only correlative relationships between Tollip and immune checkpoint molecules but also to determine the mechanistic basis and functional consequences of these relationships.

What techniques can researchers use to investigate Tollip's potential role in autophagy regulation?

Recent studies suggest Tollip may modulate cellular autophagy pathways, opening new research directions:

• Autophagy Marker Analysis:

  • Western blot for LC3-I to LC3-II conversion in Tollip-deficient versus wild-type cells

  • Monitoring p62/SQSTM1 accumulation as an indicator of autophagy flux

  • Assessment of other autophagy proteins (Beclin-1, ATG proteins) in relation to Tollip expression

• Microscopy-Based Approaches:

  • Immunofluorescence co-localization studies of Tollip with LC3-positive autophagosomes

  • Live-cell imaging using fluorescently tagged Tollip and autophagy markers

  • Electron microscopy with immunogold labeling to precisely localize Tollip in autophagic structures

• Functional Autophagy Assays:

  • Autophagic flux assessment using lysosomal inhibitors (bafilomycin A1, chloroquine)

  • Autophagy substrate degradation rates in Tollip-deficient versus wild-type cells

  • Selective autophagy pathway analysis (mitophagy, xenophagy) in relation to Tollip

• Induction Conditions to Test:

  • Nutrient starvation: Basic autophagy induction using EBSS medium

  • Rapamycin treatment: mTOR-dependent autophagy pathway

  • LPS stimulation: TLR-mediated autophagy (particularly relevant given Tollip's role in TLR signaling)

These approaches can help determine whether Tollip functions as an autophagy receptor, regulator of autophagosome formation, or mediator of autophagic flux, expanding our understanding of its cellular functions beyond immune regulation.

What protocol optimizations are required for effective Western blot detection of Tollip?

Western blot detection of Tollip requires specific optimization for reliable results:

• Sample Preparation:

  • For cell lysates: Use RIPA buffer with protease inhibitor cocktail, extract on ice for 30 minutes

  • For tissue samples: Homogenize in RIPA buffer (10× volume/weight), sonicate (5 × 10-second pulses)

  • Protein loading: Load 40-60 μg of total protein for adequate Tollip detection

• Gel Electrophoresis and Transfer:

  • Use 12-15% SDS-PAGE gels for optimal resolution around 30 kDa (Tollip's molecular weight)

  • Transfer to PVDF membrane at 100V for 1 hour in wet transfer system or 15V for 45 minutes in semi-dry system

  • Verify transfer efficiency with reversible membrane staining (Ponceau S)

• Antibody Selection and Optimization:

  • Primary antibody dilution: Start at 1:500 in 3% BSA-TBST, incubate overnight at 4°C

  • Secondary antibody: Use 1:10,000 HRP-conjugated antibody matching primary antibody species

  • Consider specialized methods for enhanced detection (ECL Prime or other high-sensitivity substrates)

• Troubleshooting Common Issues:

  • Multiple bands: May indicate isoforms or post-translational modifications; validate with knockout controls

  • Weak signal: Increase protein loading, extend exposure time, or reduce antibody dilution

  • High background: Increase washing steps (5 × 5 minutes TBST), use fresh blocking solution

For reliable quantification, normalize Tollip signal to appropriate loading controls (β-actin for whole cell lysates) and include a positive control sample in each blot for inter-blot normalization.

How should researchers optimize immunohistochemistry protocols for Tollip detection in colorectal cancer tissues?

Immunohistochemical detection of Tollip in colorectal cancer tissues requires careful optimization:

• Tissue Processing and Sectioning:

  • Fixation: 10% neutral buffered formalin for 24 hours is optimal for most Tollip antibodies

  • Section thickness: 4-5 μm sections provide good resolution while maintaining tissue integrity

  • Section mounting: Use positively charged slides to prevent tissue loss during processing

• Antigen Retrieval Optimization:

  • Method testing: Compare heat-induced epitope retrieval using citrate buffer (pH 6.0) versus EDTA buffer (pH 9.0)

  • Duration optimization: Test 10, 20, and 30-minute retrieval times to determine optimal conditions

  • Cooling period: Allow 20-30 minutes of gradual cooling before proceeding to blocking

• Antibody Selection and Validation:

  • Positive controls: Include spleen or lymph node sections (high myeloid content) with each staining batch

  • Negative controls: Include sections without primary antibody and, if available, Tollip-knockout tissue

  • Antibody dilution: Perform titration experiments (1:100, 1:200, 1:500) to determine optimal concentration

• Detection System Considerations:

  • Signal amplification: For low abundance targets, consider using polymer-based detection or tyramide signal amplification

  • Counterstaining: Adjust hematoxylin timing (30-90 seconds) to avoid obscuring low-expression signals

  • Mounting media: Use media with antifade properties if fluorescent detection is employed

• Colorectal-Specific Considerations:

  • Background reduction: Extended blocking (1-2 hours) may be needed for mucin-rich areas

  • Stromal vs. epithelial analysis: Analyze Tollip expression separately in epithelial cells versus inflammatory infiltrates

  • Tumor heterogeneity: Examine multiple tumor regions to account for spatial variation

These optimizations ensure specific and reproducible Tollip detection in colorectal tissues, facilitating accurate interpretation of its expression patterns in relation to disease progression.

What flow cytometry panel design considerations are important for analyzing Tollip in neutrophils?

Designing effective flow cytometry panels for Tollip analysis in neutrophils requires careful consideration:

• Panel Design Strategy:

  • Core identification markers: Include CD11b+/Ly6G+ for mouse neutrophils or CD66b+/CD16+ for human neutrophils

  • Activation markers: Include CD62L (downregulated upon activation) and CD11b (upregulated upon activation)

  • Key functional markers: Include PD-L1 and CD80 given their regulation by Tollip

  • Additional markers: Consider CD14 and CCR5, which show altered expression in Tollip-deficient neutrophils

• Fluorochrome Selection:

  • Assign brightest fluorochromes (PE, APC) to markers with lower expression

  • Reserve dimmer fluorochromes (PerCP, APC-Cy7) for markers with higher expression

  • Account for compensation requirements by avoiding excessive spectral overlap

• Protocol Optimization:

  • Surface staining: Perform at 4°C for 30 minutes before fixation

  • Fixation: Use 2% paraformaldehyde for 15 minutes at room temperature

  • Permeabilization: Test different reagents (saponin, methanol, commercial buffers) for optimal Tollip detection

  • Intracellular staining: Extend incubation time (45-60 minutes) for intracellular Tollip detection

• Controls and Validation:

  • Include FMO (Fluorescence Minus One) controls for each marker

  • Use Tollip-knockout cells as negative controls for antibody validation

  • Include unstimulated and stimulated samples to confirm marker responsiveness

This approach ensures comprehensive and reliable analysis of Tollip expression in neutrophils in relation to their activation status and checkpoint molecule expression.

What protocols should be used for isolating functionally intact neutrophils for Tollip studies?

Neutrophil isolation for functional studies requires careful attention to preserve cell viability and prevent activation:

• Blood Neutrophil Isolation:

  • Density gradient method: Layer blood over Ficoll-Hypaque, centrifuge at 400g for 30 minutes

  • Erythrocyte removal: Use dextran sedimentation (1-2% dextran) followed by hypotonic lysis of remaining red blood cells

  • Purification: Consider magnetic negative selection for highest purity with minimal activation

• Bone Marrow Neutrophil Isolation:

  • Bone extraction: Remove femurs and tibias, flush marrow with ice-cold PBS + 2% FBS

  • Density separation: Use a 62.5% Percoll gradient, centrifuge at 1000g for 30 minutes

  • Enrichment: Use Ly6G positive selection for mouse neutrophils

• Critical Parameters for Functional Preservation:

  • Temperature: Maintain cells at 4°C throughout isolation to minimize activation

  • Media composition: Use calcium/magnesium-free buffers until functional assays begin

  • Handling: Minimize mechanical stress, avoid vortexing, use wide-bore pipette tips

  • Timing: Complete isolation within 2-3 hours to preserve viability

• Quality Control Assessments:

  • Purity: Verify >95% neutrophil purity by flow cytometry (CD11b+/Ly6G+ or CD66b+)

  • Viability: Confirm >90% viability using Trypan blue or flow cytometry-based viability dyes

  • Activation status: Check baseline CD62L and CD11b expression to confirm resting state

• GM-CSF Priming Protocol:

  • Concentration: 100 ng/ml recombinant GM-CSF in complete medium

  • Duration: 12-18 hours incubation at 37°C, 5% CO2

  • Validation: Confirm phenotypic changes (CD11b upregulation) before functional assays

These protocols ensure the isolation of neutrophils suitable for studying Tollip's role in neutrophil function, particularly in relation to their interactions with T cells and tumor environments.

How can researchers effectively design coculture experiments to study Tollip's role in neutrophil-T cell interactions?

Based on published research on Tollip's role in neutrophil-T cell interactions, an optimized coculture experimental design should include:

• Experimental Setup:

  • Plate format: 96-well U-bottom plates for optimal cell-cell contact

  • Cell numbers: 1-2 × 10^5 T cells with varying neutrophil ratios (1:1, 1:2, 1:5)

  • Duration: 72-96 hours for proliferation assessment, 24-48 hours for activation marker analysis

  • Controls: T cells alone, unstimulated T cells, isotype antibody controls

• T Cell Preparation and Analysis:

  • CFSE labeling: 5 μM CFSE for 5 minutes at room temperature, followed by thorough washing

  • Activation: Anti-CD3 coating (1-5 μg/ml) with soluble anti-CD28 (1 μg/ml)

  • Proliferation analysis: Flow cytometry for CFSE dilution in CD4+ and CD8+ T cell populations

  • Activation markers: CD69 (early), CD25 (intermediate), HLA-DR (late)

• Neutrophil Conditioning:

  • GM-CSF priming: 100 ng/ml for 12-18 hours to induce immunosuppressive phenotype

  • Wild-type vs. Tollip-deficient comparison: Use age and sex-matched mice

  • Phenotype verification: Confirm PD-L1 and CD80 expression differences before coculture

• Mechanistic Studies:

  • Blocking antibodies: Use anti-PD-L1 (10 μg/ml) and anti-CD80 (10 μg/ml) with appropriate isotype controls

  • Transwell experiments: Separate neutrophils from T cells to determine contact dependency

  • Cytokine neutralization: Block specific cytokines to identify soluble mediators

• Comprehensive Readouts:

  • T cell proliferation: CFSE dilution by flow cytometry for both CD4+ and CD8+ populations

  • Cytokine production: Measure IFN-γ, IL-2 in supernatants by ELISA

  • Neutrophil survival: Monitor neutrophil viability throughout coculture period

  • Signaling analysis: Assess STAT1/STAT5 phosphorylation status in neutrophils after coculture

This comprehensive approach allows researchers to dissect the mechanistic basis of Tollip's influence on neutrophil-mediated T cell regulation, with direct relevance to tumor immunity.

How might single-cell approaches enhance our understanding of Tollip biology in heterogeneous immune populations?

Single-cell technologies offer powerful new approaches to investigate Tollip's variable expression and function:

• Single-cell RNA-seq Integration:

  • CITE-seq approaches combining surface antibody tagging with Tollip transcript detection

  • Correlation of Tollip protein versus mRNA expression at single-cell level

  • Identification of genes co-expressed with Tollip across immune cell subsets

• Mass Cytometry Applications:

  • Metal-conjugated Tollip antibodies in 30+ parameter panels

  • Simultaneous measurement of surface markers, intracellular Tollip, and phospho-proteins

  • Analysis of rare neutrophil subpopulations in tumor microenvironments

• Spatial Transcriptomics:

  • Mapping Tollip expression in tissue contexts while preserving spatial information

  • Analysis of Tollip+ cell localization relative to tumor boundaries or inflammatory foci

  • Correlation with expression of immune checkpoint molecules in the same microenvironments

• Potential Research Applications:

  • Tumor microenvironment: Identify distinct neutrophil phenotypes based on Tollip expression

  • Inflammatory diseases: Profile Tollip expression patterns in patient samples in relation to disease activity

  • Development: Track Tollip expression during myeloid cell differentiation and maturation

These single-cell approaches may reveal previously unrecognized heterogeneity in Tollip expression and function, potentially identifying specialized cellular subsets with distinct roles in immunity and cancer.

What are promising strategies for investigating Tollip's potential as a therapeutic target in colorectal cancer?

Given Tollip's role in colorectal cancer development, several therapeutic targeting strategies warrant investigation:

• Genetic Manipulation Approaches:

  • Neutrophil-specific Tollip knockout models to confirm cell-specific effects

  • Inducible systems for temporal control of Tollip expression

  • CRISPR-based screening to identify synthetic lethal interactions with Tollip modulation

• Small Molecule Development:

  • High-throughput screening to identify Tollip inhibitors

  • Structure-based drug design targeting specific Tollip domains

  • Repurposing of drugs affecting pathways downstream of Tollip

• Immunotherapy Combinations:

  • Testing Tollip modulation in combination with immune checkpoint blockade (anti-PD-1/PD-L1)

  • Evaluation of Tollip targeting with adoptive T cell therapies

  • Combined targeting of neutrophil and T cell pathways

• Translational Research Directions:

  • Analysis of Tollip expression in human colorectal cancer patient cohorts

  • Correlation with treatment response and survival outcomes

  • Development of biomarkers based on Tollip and related pathway components

• Therapeutic Delivery Strategies:

  • Nanoparticle-based delivery of Tollip siRNA to myeloid cells

  • Neutrophil-targeting antibody-drug conjugates

  • Cell-based therapies using ex vivo modified neutrophils

These approaches could help translate the fundamental biological insights about Tollip into novel therapeutic strategies for colorectal cancer and potentially other inflammatory diseases.